Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Accumulated Expenses (2016 - 2025)

Cardiff Oncology's Accumulated Expenses history spans 14 years, with the latest figure at $2.7 million for Q4 2024.

  • For Q4 2024, Accumulated Expenses fell 64.72% year-over-year to $2.7 million; the TTM value through Dec 2024 reached $2.7 million, down 64.72%, while the annual FY2024 figure was $2.7 million, 64.72% down from the prior year.
  • Accumulated Expenses for Q4 2024 was $2.7 million at Cardiff Oncology, down from $7.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $7.8 million in Q4 2023 and bottomed at $2.7 million in Q4 2024.
  • The 5-year median for Accumulated Expenses is $4.6 million (2023), against an average of $4.8 million.
  • The largest annual shift saw Accumulated Expenses surged 74.81% in 2022 before it plummeted 64.72% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $3.9 million in 2020, then rose by 4.13% to $4.0 million in 2021, then grew by 29.1% to $5.2 million in 2022, then skyrocketed by 50.34% to $7.8 million in 2023, then plummeted by 64.72% to $2.7 million in 2024.
  • Per Business Quant, the three most recent readings for CRDF's Accumulated Expenses are $2.7 million (Q4 2024), $7.2 million (Q3 2024), and $6.7 million (Q2 2024).